Fig. 4
The combination of OH2 and anti-SIRPα therapy enhances anticancer immune responses in vivo. A The expression levels of CD47 and SIRPα in CT26, MC38, and 4T-1 cell lines were detected by flow cytometry. B The treatment process and the experimental timeline for adjusted combined treatment. C The tumour growth curve of different treatment groups of tumour-bearing mice with larger tumour volumes at the initial treatment. The red box zoomed in to show the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, and OH2 group. Two-way analysis of variance (ANOVA) was performed on the experimental data. n=10 mice/group. *, p=0.019. D The survival curve of different treatment groups of tumour-bearing mice with larger tumour volumes at the initial treatment. The Kaplan-Meier method and log-rank test were used for the survival curve data. *, p=0.041. E The tumour growth curve of the OH2 combined anti-SIRPα antibody group, anti-SIRPα antibody group, OH2 group, and control group. Two-way analysis of variance (ANOVA) was performed on the experimental data. n=6 mice/group. *; **. F The survival curve of the OH2 combined anti-SIRPα antibody group, anti-SIRPα antibody group, OH2 group, and control group. The Kaplan-Meier method and log-rank test were used for the survival curve data. *, p=0.0183. G The treatment process and experimental timeline for the combined treatment. H The tumour growth curve of the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, and control group. Two-way analysis of variance (ANOVA) was performed on the experimental data. n=7 mice/group. *, p=0.029; **, P=0.0041; ***, p=0.0003. I The survival curve of the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, and control group. The Kaplan-Meier method and log-rank test were used for the survival curve data. *, p=0.03 and p=0.018; **, P=0.0014